CytoDyna??s Leronlimab Prevents Transmission of SHIV in Macaque Study

Results of preclinical study presented today in oral presentation at the 23rd International AIDS Conference (AIDS 2020)A  VANCOUVER, Washington, July 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (a??CytoDyna?? or the a??Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential clinical indications for HIV, COVID-19, cancer, GvHD and NASH announced today the results from a preclinical macaque study evaluating leronlimab as pre-exposure prophylaxis (PrEP) to prevent sexual HIV transmission. The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques. These results were presented today in an oral presentation titled a??CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition" at the 23rd International AIDS Conference (AIDS 2020).a??The results reported here in the preclinical macaque model of HIV sexual transmission support leronlimab as a possible PrEP agent at a time when long-acting human HIV PrEP options are limited,a?? said Dr. Jonah Sacha, Professor at Oregon Health & Science University, and the studya??s lead investigator.a??We are eager to build upon these preclinical results describing leronlimaba??s utility in HIV prevention by initiating clinical studies for leronlimab as a PrEP treatment. Current PrEP options require a continued daily dosing regimen in order to be effective and are inherently difficult to maintain in the long-term,a?? said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. a??Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection,a?? concluded Dr. Pourhassan.About Coronavirus Disease 2019
CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2022    »